Abstract
Matrix stiffening with downstream activation of mechanosensitive pathways is strongly implicated in progressive fibrosis; however, pathologic changes in extracellular matrix (ECM) that initiate mechano-homeostasis dysregulation are not defined in human disease. By integrated multiscale biomechanical and biological analyses of idiopathic pulmonary fibrosis lung tissue, we identify that increased tissue stiffness is a function of dysregulated post-translational collagen cross-linking rather than any collagen concentration increase whilst at the nanometre-scale collagen fibrils are structurally and functionally abnormal with increased stiffness, reduced swelling ratio, and reduced diameter. In ex vivo and animal models of lung fibrosis, dual inhibition of lysyl oxidase-like (LOXL) 2 and LOXL3 was sufficient to normalise collagen fibrillogenesis, reduce tissue stiffness, and improve lung function in vivo. Thus, in human fibrosis, altered collagen architecture is a key determinant of abnormal ECM structure-function, and inhibition of pyridinoline cross-linking can maintain mechano-homeostasis to limit the self-sustaining effects of ECM on progressive fibrosis.
Keywords:
biomechanics; collagen; extracellular matrix; fibrosis; human; human biology; lung; lysyl oxidase; medicine; mouse.
© 2018, Jones et al.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Oxidoreductases / antagonists & inhibitors*
-
Amino Acid Oxidoreductases / genetics
-
Amino Acid Oxidoreductases / metabolism
-
Amino Acids / chemistry
-
Animals
-
Biomechanical Phenomena
-
Case-Control Studies
-
Collagen / chemistry*
-
Collagen / metabolism
-
Collagen / ultrastructure
-
Cross-Linking Reagents / chemistry
-
Disease Models, Animal
-
Enzyme Inhibitors / pharmacology*
-
Extracellular Matrix / chemistry*
-
Extracellular Matrix / metabolism
-
Extracellular Matrix / ultrastructure
-
Female
-
Fibroblasts / cytology
-
Fibroblasts / drug effects
-
Fibroblasts / metabolism
-
Gene Expression
-
Homeostasis / genetics
-
Humans
-
Lung / metabolism
-
Lung / pathology
-
Mechanotransduction, Cellular
-
Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase / antagonists & inhibitors
-
Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase / genetics
-
Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase / metabolism
-
Protein-Lysine 6-Oxidase
-
Pulmonary Fibrosis / drug therapy*
-
Pulmonary Fibrosis / genetics
-
Pulmonary Fibrosis / metabolism
-
Pulmonary Fibrosis / pathology
-
Rats
-
Rats, Sprague-Dawley
-
Reticulin / chemistry*
-
Reticulin / metabolism
-
Reticulin / ultrastructure
-
Structure-Activity Relationship
-
Transforming Growth Factor beta1 / antagonists & inhibitors
-
Transforming Growth Factor beta1 / pharmacology
Substances
-
Amino Acids
-
Cross-Linking Reagents
-
Enzyme Inhibitors
-
Reticulin
-
TGFB1 protein, human
-
Transforming Growth Factor beta1
-
pyridinoline
-
Collagen
-
PLOD2 protein, human
-
Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase
-
Amino Acid Oxidoreductases
-
LOXL2 protein, human
-
LOXL3 protein, human
-
LOXL4 protein, human
-
Protein-Lysine 6-Oxidase